Joel Greenblatt’s BridgeBio Pharma BBIO Stock Holding History

Joel Greenblatt’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,486	Closed	-$343K	–	1377
2023 Q4	$343K	Buy	+8,486	New	+$255K	0.01%	1099

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Joel Greenblatt's BBIO Position: Q1 2024 in Review

Joel Greenblatt sold out of BridgeBio Pharma (BBIO) in Q1 2024, closing a stake of 8,486 shares — an estimated $343K sold.

Joel Greenblatt first reported a position in BBIO in Q4 2023 and held it in 1 quarter. The position peaked at $343K in Q4 2023. 244 funds tracked by Wall St. Rank hold BBIO as of Q1 2024.

Joel Greenblatt reported no remaining BridgeBio Pharma position as of Q1 2024 after selling out during the quarter.
Joel Greenblatt sold 8,486 BridgeBio Pharma shares in Q1 2024, an estimated $343K.
Joel Greenblatt first reported a position in BridgeBio Pharma in Q4 2023 and held it in 1 quarter.
Joel Greenblatt's BridgeBio Pharma position peaked at $343K in Q4 2023.
244 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2024.

Based on Gotham Asset Management's 13F filing for Q1 2024, filed 15 May 2024.